Prioritizing new malaria vaccine candidates for further development
Prioritizing new malaria vaccine candidates for further development
Prioritizing new malaria vaccine candidates for further development
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Updating the Malaria Vaccine Technology Roadmap<br />
Expanded Strategic Goals – Part 1 (draft)<br />
Strategic Goals after first<br />
public consultation in Oct 2012<br />
In the 2025 to 2050 timeframe, license<br />
safe <strong>vaccine</strong>s targeting <strong>malaria</strong><br />
species with significant global disease<br />
burden and encompassing the<br />
following two objectives, <strong>for</strong> use by the<br />
international public health community 1 :<br />
1) Malaria <strong>vaccine</strong>s with a protective<br />
efficacy of more than 80% 2 against<br />
clinical <strong>malaria</strong>, suitable <strong>for</strong><br />
administration to both children and<br />
adults in <strong>malaria</strong>-endemic areas. The<br />
efficacy measure will be an 80%<br />
absolute reduction in incidence of all<br />
episodes of clinical <strong>malaria</strong> over at least<br />
2 years. 3<br />
New strategic goal <strong>for</strong><br />
disease prevention<br />
• Protective efficacy of more<br />
than 80%<br />
• Clinical <strong>malaria</strong><br />
• Over at least 2 years<br />
• Children and adults<br />
• Includes all <strong>malaria</strong>endemic<br />
areas<br />
http://www.who.int/<strong>vaccine</strong>_research/diseases/<strong>malaria</strong>/<br />
Roadmap_update_<strong>for</strong>_second_public_consultation.pdf<br />
13
Change language